A Bayesian-frequentist two-stage single-arm phase II clinical trial design

Statistics in Medicine

Volumn 31, Issue 19, 2012, Pages 2055-2067

  Dong, Gaohong ^a   Shih, Weichung Joe ^b   Moore, Dirk ^b   Quan, Hui ^c   Marcella, Stephen ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c SANOFI   (France)

Author keywords

Bayesian Type I and Type II error rates; Expected sample size; Frequentist Type I and Type II error rates; Predictive probability; Probability of early termination

Indexed keywords

ARTICLE; BAYES THEOREM; BAYESIAN FREQUENTIST TWO STAGE DESIGN; BINOMIAL DISTRIBUTION; MATHEMATICAL MODEL; PHASE 2 CLINICAL TRIAL (TOPIC); PROBABILITY; SAMPLE SIZE; SENSITIVITY ANALYSIS;

BAYES THEOREM; BIAS (EPIDEMIOLOGY); BINOMIAL DISTRIBUTION; CLINICAL TRIALS, PHASE II AS TOPIC; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; HUMANS; MODELS, STATISTICAL; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84864020956     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5330     Document Type: Article

References (25)

1. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989; 10(1):1-10.
2. Shuster J. Optimal two-stage designs for single arm phase II cancer trials. Journal of Biopharmaceutical Statistics 2002; 12(1):39-51.
3. Fleming TR. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38:143-151.
4. Chang MN, Therneau TN, Wieand HS, Cha SS. Designs for group sequential phase II clinical trials. Biometrics 1987; 43:865-874.
5. Chen TT, Ng TH. Optimal flexible designs in phase II clinical trials. Statistics in Medicine 1998; 17(20):2301-2312.
6. Lin Y, Shih WJ. Adaptive two stage designs for single-arm phase IIA cancer clinical trials. Biometrics 2004; 60(2):482-490.
7. Shih WJ. Sample size re-estimation - journey for a decade. Statistics in Medicine 2001; 20(1):515-518.
8. Tan SB, Machin D. Bayesian two-stage designs for phase II clinical trials. Statistics in Medicine 2002; 21(14):1991-2012.
9. Mayo MS, Gajewski BJ. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors. Controlled Clinical Trials 2004; 25:157-167.
10. Sambucini V. A Bayesian predictive two-stage design for phase II clinical trials. Statistics in Medicine 2008; 27(8):1199-1224.
11. Lee SJ, Zelen M. Clinical trials and sample size considerations: Another perspective (with discussion). Statistical Science 2000; 15:95-110.
12. Simon R. Commentary on clinical trials and sample size considerations: Another perspective (by Lee & Zelen). Statistical Science 2000; 15:103-105.
13. Bryant JL, Day RS. Commentary on clinical trials and sample size considerations: Another perspective (by Lee & Zelen). Statistical Science 2000; 15:106-108.
14. Wang YG, Leung DHY, Li M, Tan SB. Bayesian designs with frequentist and Bayesian error rate considerations. Statistical Methods in Medical Research 2005; 14:445-456.
15. Herson J. Predictive probability early termination plans for phase II clinical trials. Biometrics 1979; 35:775-783.
16. Lee JJ, Liu DD. A predictive probability design for phase II cancer. Clinical Trials 2008; 5:93-106.
17. Berry DA. A guide to drug discovery: Bayesian clinical trials. Nature Reviews Drug Discovery 2006; 5:27-36.
18. Food and Drug Administration (FDA). Guidance for the use of Bayesian statistics in medical device clinical trials, 2010. Available from: [accessed Nov 6, 2010].
19. Chang M, Chow SC. A hybrid Bayesian adaptive design for dose response trials. Journal Biopharmaceutical Statistics 2005; 15:677-691.
20. Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Statistics in Medicine 2007; 26:4687-4702.
21. Green SJ, Dahlberg S. Planned versus attained design on phase II clinical trials. Statistics in Medicine 1992; 11(7):853-862.
22. Wu Y, Shih WJ. Approaches to handling data when a phase II trial deviates from the pre-specified Simon's two-stage design. Statistics in Medicine 2008; 27(29):6190-6208.
23. Tao A. A dose-finding method in joint modeling of efficacy and safety endpoints in phase II studies: An extension of the MCP-Mod method. Ph. D. Dissertation, University of Medicine and Dentistry of New Jersey, 2010.
24. Johnson VE, Cook JD. Bayesian design of single-arm phase II clinical trials with continuous monitoring. Clinical Trials 2009; 6:217-26.
25. Johnson V, Rossell D. On the use of non-local prior densities in Bayesian hypothesis tests. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 2010; 72(2):143-170.